iBET at PEGS Europe 2025: Advancing Biopharmaceuticals’ Development
November 18, 2025
From multispecific antibodies to 3D tumour models and next-generation vaccines
A team of 17 iBET scientists recently participated in the 17th Annual Protein and Antibody Engineering Summit (PEGS) Europe, held in Lisbon from 11-13 November.
iBET actively contributed to the conference program with 4 oral and 3 poster presentations, highlighting the institute’s expertise in the topics of antibodies, cell models, protein analytics and vaccines development.
Oral Presentations
- Catarina Brito – “A Molecular Platform of Reconstructive 3D-Cell Models of Tumour Microenvironments to Evaluate Antibody-Based Therapies”
- Daniel Simao – “Exploring Monocyte-Derived Macrophage Phenotypes as a Therapeutic Target in Cardiac Fibrosis”
- Jose Escandell – “Optimising Vector Design for High-Quality Multispecific Antibody Production”
- Alessio Bortoluzzi – “Enabling Mode-of-Action Studies of TEAD1 Ligands through Hydrogen Deuterium Exchange Mass-Spectrometry and Tailored Protein Purification Workflows”
Catarina Brito (top left), Daniel Simão (top right), Jose Escandell (bottom left), and Alessio Bortoluzzi (bottom right) presenting their research at PEGS2025.
Poster Presentations
- Sofia Carvalho – “Bioanalytics for Mispairing Profiling of Multispecific Antibodies: Impact on Bioprocess Design”
- Patrícia Gomes-Alves – “Assessing Omic Mispairing Signatures in Chinese Hamster Ovary (CHO) Cells Producing a Tri-Specific Antibody”
- Rute Catro – “Enabling Next-Generation Poliovirus VLP Vaccines Through Bioprocess Engineering”
The event provided a valuable platform for knowledge exchange and networking, reinforcing iBET’s commitment to advancing innovation in biopharmaceutical research.
